Originally posted by ymc
View Post
-
Matching the error rate of PacBio would indeed be pretty impressive, but that alone is insufficient to kill off PacBio or Illumina. The question is does the ONT error profile match that of PacBio? In other words, is it stochastic and relatively free of GC bias so that at sufficient coverage the consensus error rate drops to very low levels (like PacBio). Or does it suffer from systematic errors that create a ceiling to the consensus read quality? Have these questions been definitely answered yet? -
If the accuracy of R9 chemistry plus RNN algorithm is true, then both PacBio and Illumina will be dead.
However, judging from ONT's past record, this might well be achievable but the timeline is more likely to be one or two years in the future. As a result, this lawsuit can still be a distraction for ONT for the time being IMHO.Leave a comment:
-
A Hammer Thrown at Big Brother?
Oxford Nanopore Technologies, the company that pioneered a new DNA analysis technique called nanopore sequencing, has remained secretive about the microscopic channel at the heart of its products. But on the heels of a patent infringement lawsuit from sequencing behemoth Illumina, Inc., the company has revealed what will drive its newest devices—a bacterial pore that seems to circumvent Illumina’s challenge.
...
A webcast presentation today for customers of the company will likely put many of those fears to rest. Oxford Nanopore’s Chief Technology Officer Clive Brown announced an upgrade to its devices—a new pore the company has been describing in presentations as R9. Brown revealed that R9 is CsgG, a membrane protein derived from Escherichia coli, but present in many bacterial species.
http://www.sciencemag.org/news/2016/...new-technology
-
Proteins are often described as the workhorses of the cell, and identifying their sequences is key to understanding their role in biological processes and disease. Currently, the most common technique used to determine protein sequences is mass spectrometry. While still a valuable tool, mass spectrometry faces several limitations and requires a highly experienced scientist familiar with the equipment to operate it. Additionally, other proteomic methods, like affinity assays, are constrained...04-04-2024, 04:25 PM -
Despite advancements in sequencing platforms and related sample preparation technologies, certain sample types continue to present significant challenges that can compromise sequencing results. Pedro Echave, Senior Manager of the Global Business Segment at Revvity, explained that the success of a sequencing experiment ultimately depends on the amount and integrity of the nucleic acid template (RNA or DNA) obtained from a sample. “The better the quality of the nucleic acid isolated...03-22-2024, 06:39 AM
Leave a comment: